Indomethacin pretreatment in continuous positive-pressure ventilation

Area of Science:

• Cardiovascular Physiology
• Pulmonary Medicine
• Pharmacology

Background:

• Continuous positive-pressure ventilation (CPPV) can induce significant cardiovascular and pulmonary complications.
• Prostaglandins (PG) and thromboxanes (TX) are implicated in inflammatory and vascular responses.
• Understanding the role of these mediators is crucial for managing mechanically ventilated patients.

Purpose of the Study:

• To investigate the involvement of prostaglandins (PG) and thromboxanes (TX) in CPPV-induced cardiovascular and pulmonary alterations.
• To determine if inhibiting PG and TX synthesis can mitigate these adverse effects.

Main Methods:

• Dogs were subjected to CPPV with or without indomethacin (IND), a cyclo-oxygenase inhibitor.
• Pulmonary edema, alveolar hemorrhage, lung compliance, cardiac index (CI), and left ventricular dP/dt max were assessed.
• Measurements were compared between the buffer and CPPV + IND groups.

Main Results:

• CPPV alone led to pulmonary edema, hemorrhage, decreased lung compliance, and reduced cardiac index and left ventricular contractility.
• Indomethacin pretreatment largely prevented lung tissue damage and maintained normal lung compliance.
• IND administration attenuated the reduction in cardiac index and altered the pattern of cardiac depressant effects.

Conclusions:

• Prostaglandins and thromboxanes appear to mediate lung injury and cardiovascular dysfunction during CPPV.
• Inhibition of PG and TX synthesis with indomethacin offers protection against CPPV-induced damage.
• These findings suggest a potential therapeutic strategy for mitigating CPPV-related complications.